SCHEMBL31367546

SCHEMBL31367546

CC(=O)c1ccc(-c2cc(-c3ccc(Br)cc3)cn3cc(-c4ccccc4)nc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 5/20 0.50
ALDH1A1 P00352 3/20 0.50
ALDH1A2 O94788 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 2/20 0.44
DHODH Q02127 1/20 0.44
TMIGD3 P0DMS9 6/20 0.44
ADORA3 P0DMS8 1/20 0.43
MCL1 Q07820 1/20 0.43
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
POLB P06746 2/20 0.41
RAB9A P51151 2/20 0.41
ADORA1 P30542 1/20 0.41
GAA P10253 1/20 0.41
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
SGK1 O00141 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31367528 0.94 ALDH1A3 (0.55) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL31367620 0.90 ALDH1A3 (0.53) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL31367516 0.89 ALDH1A3 (0.55) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL31367433 0.89 ALDH1A3 (0.55) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL31367417 0.89 ALDH1A3 (0.55) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL31367469 0.88 ALDH1A1 (0.67) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL31367425 0.88 ALDH1A3 (0.54) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL31367558 0.88 ALDH1A3 (0.54) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL973321 0.88 ALDH1A3 (0.54) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL31367536 0.86 ALDH1A3 (0.52) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP claimed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US claimed
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP disclosed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A ALDH2, ALDH3A1, ALDH1A1 ALDH1A3 8/4885ALDH1A1 3/4885ALDH1A2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.